Isolation of a normal B cell subset with a Burkitt‐like phenotype and transformation in vitro with Epstein‐Barr virus

Epstein‐Barr virus (EBV) is causally linked with endemic Burkitt's lymphoma (BL), a tumour whose homogeneous cell surface phenotype suggests derivation from a particular subset of activated germinal centre B cells in vivo. Endemic BL also shows an unusual form of EBV in fection with downregulation of certain of the virus latent proteins which are constitutively expressed when EBV infects and transforms normal resting B cells in vitro. Here we question whether this virus:cell interaction is unique to malignant BL cells or whether it might be reproduced by in vitro infection of those particular germinal centre cells displaying the BL‐like phenotype. Firstly, we show by biochemical meanns that a subset of normal tonsillar B cells does indeed express the globotriaosylceramide glycolipid BLA and the common acute lymphoblastic leukaemia antigen CALLA, 2 important markers of the BL phenotype. Secondly, using 2‐colour immunofluorescence labelling with anti‐BLA and anti‐CALLA monoclonal antibodies (MAbs), 4 subsets of low buoyant density tonsillar B cells (BLA+ CALLA+, BLA+ CALLA−, BLA− CALLA+, BLA− CALLA−) have been separated by means of a FACS and tested for their susceptibility to EBV‐induced growth transfromation in a limiting dilution assay. The BLA+ CALLA+ (i. e., BL‐like) subset contained the highest proportion of cells already actively in cycle in vivo and gave the lowest yield of transformants, perhaps reflecting the greater efficiency with which EBV transforms resting target cells. Of the cell lines established from the BLA+ CALLA+ population, a significant number retained BLA expression but CALLA was always lost. In 2 further respects, these lines resembled conventional in vitro transformants rather than lines of BL type; thus the cells expressed cellular “activation” antigens (CD23, CD39, CD30, Ki‐24) characteristic of the lymphoblastoid phenotype and contained the full spectrum of EBV latent proteins.

[1]  L. Young,et al.  Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.

[2]  M. Lipinski,et al.  Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. , 1987, Journal of immunology.

[3]  E. Kieff,et al.  Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. , 1987, The Journal of general virology.

[4]  S. Swendeman,et al.  The activation antigen BLAST‐2, when shed, is an autocrine BCGF for normal and transformed B cells. , 1987, The EMBO journal.

[5]  E. Kieff,et al.  Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[6]  H. Strander,et al.  Characterization of ebv‐carrying b‐cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth , 1987, International journal of cancer.

[7]  G. Lenoir,et al.  B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation. , 1987, Journal of the National Cancer Institute.

[8]  T. Rabbitts,et al.  Epstein‐Barr virus‐transformed human precursor B cell lines: altered growth phenotype of lines with germline or rearranged but nonexpressed heavy chain genes , 1987, European journal of immunology.

[9]  G. Lenoir,et al.  EBV‐negative and ‐positive burkitt cell lines variably express receptors for B‐cell activation and differentiation , 1986, International journal of cancer.

[10]  C. Rooney,et al.  Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. , 1986, Journal of the National Cancer Institute.

[11]  D. Gray,et al.  Antigen‐Driven Selection of Virgin and Memory B Cells , 1986, Immunological reviews.

[12]  P. Åman,et al.  Surface marker characterization of EBV target cells in normal blood and tonsil B lymphocyte populations. , 1985, Journal of immunology.

[13]  G. Klein,et al.  Evolution of tumours and the impact of molecular oncology , 1985, Nature.

[14]  M. Epstein,et al.  Distinctions between endemic and sporadic forms of epstein‐barr virus‐positive burkitt's lymphoma , 1985, International journal of cancer.

[15]  G. Lenoir,et al.  Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin. , 1984, Journal of the National Cancer Institute.

[16]  G. Klein,et al.  Distinction between burkitt lymphoma subgroups by monoclonal antibodies: Relationships between antigen expression and type of chromosomal translocation , 1984, International journal of cancer.

[17]  G. Klein,et al.  Epstein-Barr virus susceptibility of normal human B lymphocyte populations , 1984, The Journal of experimental medicine.

[18]  V. Diehl,et al.  Evidence for the detection of the normal counterpart of hodgkin and sternberg‐reed cells , 2007, Hematological oncology.

[19]  P. Bourgeois,et al.  Internal mammary lymphoscintigraphy: current status in the treatment of breast cancer. , 1983, Critical reviews in oncology/hematology.

[20]  S. Hakomori,et al.  A series of human erythrocyte glycosphingolipids reacting to the monoclonal antibody directed to a developmentally regulated antigen SSEA-1. , 1982, The Journal of biological chemistry.

[21]  V. Diehl,et al.  Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells , 1982, Nature.

[22]  M. Epstein,et al.  Monoclonal antibodies to epstein‐barr virus‐induced, transformation‐associated cell surface antigens: Binding patterns and effect upon virus‐specific t‐cell cytotoxicity , 1982, International journal of cancer.

[23]  G. Klein,et al.  Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. , 1982, Advances in cancer research.

[24]  T. Tursz,et al.  Monoclonal antibody against a Burkitt lymphoma-associated antigen. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Nadler,et al.  Expression of cell surface markers after human B lymphocyte activation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Magnani,et al.  Detection of gangliosides that bind cholera toxin: direct binding of 125I-labeled toxin to thin-layer chromatograms. , 1980, Analytical biochemistry.

[27]  G. Klaus,et al.  The Follicular Dendritic Cell: Its Role in Antigen Presentation in the Generation of Immunological Memory , 1980, Immunological reviews.

[28]  H. Lazarus,et al.  A monoclonal antibody to human acute lymphoblastic leukaemia antigen , 1980, Nature.

[29]  J. Robinson,et al.  Surface markers and size of lymphocytes in human umbilical cord blood stimulated into deoxyribonucleic acid synthesis by Epstein-Barr Virus , 1979, Infection and immunity.

[30]  M. Epstein,et al.  The Relationship of the Virus to Burkitt’s Lymphoma , 1979 .

[31]  G. Miller,et al.  COMPARISON OF THE YIELD OF INFECTIOUS VIRUS FROM CLONES OF HUMAN AND SIMIAN LYMPHOBLASTOID LINES TRANSFORMED BY EPSTEIN-BARR VIRUS , 1973, The Journal of experimental medicine.

[32]  J. H. Pope,et al.  Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. , 1972, The Journal of general virology.

[33]  T. Saito,et al.  Quantitative isolation of total glycosphingolipids from animal cells. , 1971, Journal of lipid research.